A randomised study to optimise clinical outcomes in patients with FLT3 mutant AML

急性骨髓性白血病是一种毁灭性的血癌，每年影响近1000名澳大利亚人。四分之一的人有一种影响FLT3基因的突变，这种突变导致侵袭性白血病，很少单独通过化疗治愈。来自阿尔弗雷德医院的Andrew Wei博士将通过澳大利亚白血病和淋巴瘤组织网络领导一项全国性的随机临床试验，以研究一种名为索拉非尼的靶向FLT3抑制剂小分子是否会改善这种低风险血癌患者的预后。

Acute myeloid leukaemia is a devastating blood cancer which affects almost 1000 Australians annually. One quarter have a mutation affecting a gene called FLT3, which results in aggressive leukaemia rarely cured by chemotherapy alone. Dr Andrew Wei from the Alfred Hospital will lead a nationwide randomised clinical trial through the Australasian Leukaemia and Lymphoma Group network to investigate whether a targeted FLT3 inhibitor small molecule called Sorafenib will improve outcomes for patients with this poor risk blood cancer.